David R. Minor

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.7K citations · Full text

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015 · 2.6K citations

Checkmate 037, Medicine, Melanoma +9

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

F. Stephen Hodi, Jason Chesney, Anna C. Pavlick et al. · The Lancet Oncology · 2016 · 967 citations

Oncology, Melanoma, Clinical Trials +8

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

Jeffrey S. Weber, John A. Thompson, Omid Hamid et al. · Clinical Cancer Research · 2009 · 563 citations · Full text

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

Igor Puzanov, Mohammed Milhem, David R. Minor et al. · Journal of Clinical Oncology · 2016 · 542 citations · Full text